By Professor Jason Grebely

Conference Abstracts

Grebely J; Mauss S; Brown A; Bronowicki J-P; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION RECEIVING OPIOID SUBSTITUTION THERAPY: PHASE 3 ION TRAILS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 41

Alavi M; Janjua N; Yu A; Grebely J; Aspinall E; Innes H; Valerio H; Hayes P; Krajden M; Amin J; Law M; George J; Goldberg D; Hutchinson S; Dore G, 2016, 'DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S462 - S463, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00776-5

Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1

Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40

Alavi M; Grebely J; Micallef M; Dunlop A; Balcomb A; Day C; Treloar C; Bath N; Haber P; Dore G, 2015, 'P0883 : Treatment for hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ethos study', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, Vol. 62, pp. s673, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31085-0

Reports

Wilkinson A; Griffin S; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Aitken C; Broady T; Combo T, 2023, Australia’s progress towards hepatitis C elimination: Annual Report 2023, http://dx.doi.org/10.26190/4d4f-5n41

Shahbazi J; Farrell M; Byrne J; Ali R; Puszka B; Lim XQ; Cook J; Weiss R; Rodgers C; Dunlop A; Lintzeris N; Nielsen S; Grebely J; Zahra E; Degenhardt L; Byrne M, 2023, Considerations for delivering extended-release buprenorphine for opioid dependence in Australia: Preliminary lessons from the Community Long-Acting Buprenorphine (CoLAB) trial, NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2020, RANDWICK, 355, http://dx.doi.org/10.26190/zemp-dx93

Wilkinson A; Hayes M; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Alavi M; Aitken C; Broady T; Combo T, 2022, Australia's progress towards hepatitis C elimination: annual report 2022, http://dx.doi.org/10.26190/ge22-aq55

Brothers T; Degenhardt L, 2022, Time periods of altered risk for severe injection drug use-associated skin and soft-tissue infections: protocol for a self-controlled case series in New South Wales, Australia, 2001-2018, UCL Press, http://dx.doi.org/10.14324/000.rp.10157481, http://dx.doi.org/10.14324/000.rp.10157481

Bajis S; Dore G; Alavi M; McGregor S; Kwon A; Monaghan R; Iversen J; Martinello M; Buckland G; Guy R; Kaldor J; Grebely J, 2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, UNSW Sydney, Sydney, Australia, https://kirby.unsw.edu.au/report/progress-towards-hepatitis-c-elimination-among-aboriginal-and-torres-strait-islander-people

Wilkinson A; Hellard M; Pedrana A; Alavi M; Stoove M; Doyle J; Aitken C; Dore G; Thompson A; Broady T; Grebely J; Hajarizadeh B, 2020, Australia’s progress towards hepatitis C elimination: annual report 2020, Burnet Institute and Kirby Institute, http://dx.doi.org/10.26190/unsworks/28056, https://kirby.unsw.edu.au/report/australias-progress-towards-hepatitis-c-elimination-annual-report-2020

Gibbs D; Grebely J; Larney S; Butler K; Sutherland R; Starr M; Karlsson A; Uporova J; Degenhardt L; Farrell M; Peacock A, 2019, Self-report and serological HCV status amongst people who inject drugs in NSW and ACT, National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Drug Trends Bulletin August 2019, http://dx.doi.org/10.26190/5d788a487ac61, https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/4.%20DBS%20and%20HCV%20self%20report%20bulletin.pdf

Wilkinson A; Hellard M; Pedrana A; Alavi M; Stoove M; Doyle J; Aitken C; Dore G; Thompson A; Grebely J; Hajarizadeh B, 2019, Australia’s progress towards hepatitis C elimination: annual report 2019, Burnet Institute and Kirby Institute, http://dx.doi.org/10.26190/unsworks/28055, https://kirby.unsw.edu.au/report/australias-progress-towards-hepatitis-c-elimination-annual-report-2019

Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney

Theses / Dissertations

Valerio H, 2021, Elimination of hepatitis C virus among people who inject drugs in Australia

Bartlett SR, 2017, Molecular epidemiology of recently acquired hepatitis C virus infection in Australia

Preprints

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824

Other

Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, Elsevier, http://dx.doi.org/10.1016/j.jhep.2017.03.035

Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, Elsevier, http://dx.doi.org/10.1016/j.jhep.2016.12.028

Back to profile page